Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|August 8, 2025
NSCLC Experts Highlight Clinical Trials to Watch in 2025
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Lung cancer experts share upcoming, potentially practice-informing clinical trials that are expected to read out in the second half of 2025.
Advertisement
Advertisement
The non–small cell lung cancer (NSCLC) treatment paradigm is rapidly evolving, with multiple clinical trials poised to reshape standards of care for several patient subgroups. OncLive® asked leading lung cancer experts to share the research and readouts they’re most highly anticipating over the next few months. We heard from:
Related to this article
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Advertisement
Advertisement